H epatitis C virus (HCV) infection
remains a major public health problem given that an estimated 71 million people are currently infected and 1.75 million are newly infected every year. Up to 85% of HCV infections become persistent and may eventually lead to chronic liver diseases, including cirrhosis and hepatocellular carcinoma. 1 Immune responses play a crucial role in virus control and liver injury; however, the underlying mechanism is not completely understood. Patients chronically infected with HCV generally exhibit a weak peripheral blood T cell response against HCV, which could explain viral persistence. As cells that play a key role in dominant immune tolerance, regulatory T (T-reg) cells suppress inflammatory responses and prevent the development of autoimmune diseases. CD4 + CD25 + Foxp3 + T-reg cells, which are divided into natural T-reg (nT-reg) cells or thymus-derived T-reg cells and induced T-reg (iT-reg) cells or peripherally derived T-reg cells, also suppress antiviral T cell responses and protect the liver from immune-mediated damage in chronic HCV infection. 2 T-reg cells control HCV-specific T cells not only in persistent infection but also after recovery, where they may regulate memory T cell responses by controlling their activation and preventing apoptosis. 3 In this commentary, we discuss whether activated T-reg cells and non-functional effector cells are the causes or consequences of chronic HCV infection.
HCV encodes several immunomodulatory proteins, such as HCV core protein (HCVc), envelope proteins and nonstructural proteins, all of which help to evade host immune defense. HCVc is a major component of HCV nucleocapsids and exhibits various biological functions, including immunomodulatory activity. HCVc induces an inflammatory cascade in human monocytes, macrophages, and Kupffer cells via engagement with TLR2. 4 HCV, including its encoded proteins, induces T-reg cell expansion by several different viral pathways as shown in Figure 1 . In a recent paper, we discovered that HCVc can directly activate regulatory CD4 + T cells and thereby suppress effector CD4 + T-cell proliferation and function through IL-10 and TGF-β. We identified that HCVc and lipoteichoic acid (LTA) affect CD4 + CD25 + T-reg cells but not naive CD4 + T cells. 5 The negative regulatory factor (nef) protein of HIV increases T-reg cells via TLR2. 6 Thus, this mechanism is likely to occur in diverse viruses. In addition, T-reg cells can be indirectly induced via activation of other cells. We recently reported that HCV induces myeloidderived suppressor cells (MDSCs) through a TLR2/PI3K/AKT/STAT3 signaling pathway to educate T-reg cells and inhibits autologous CD4 + T-cell activation. 7 In HCV infection, the primary site of HCV replication is within hepatocytes. HCV-infected hepatocytes express increased levels of Gal-9 and TGF-β, causing upregulation of Tim-3 expression and the regulatory cytokines TGF-β and IL-10 in co-cultured CD4 + T cells and subsequently driving conventional CD4 + T cells to differentiate into CD25 + Foxp3 + T-reg cells. 8 More recently, we found that HBV-induced regulatory NK (NK-reg) cells via monocytes inhibit both autologous T-cell activation and HBV-specific T cell response in an IL-10-dependent manner. 9 To our knowledge, there is no study on NK-reg cell-mediated effects of HCV proteins in other cell types. Whether NK-reg cells expand and their influence on T-reg cells in chronic HCV infection require further investigation.
The picture our paper paints is that activated CD4 + T-reg cells co-exist with viremia and functionally impaired effector CD4 + T cells in chronic HCVinfected patients, 5 and the work of others have demonstrated that CD8 + T cells are functionally impaired. The issue arises regarding the extent to which the CD4 + and CD8 + T-cell dysfunction is a result of viremia given that HCVc drives it via T-reg cells. 5 In addition, the extent to which T-cell dysfunction is the cause of the viremia also remains a question given that Grakoui et al. 10 demonstrated that viral containment depends on functional T cells. The emergence of viruses with mutations in class I MHC-restricted epitopes is the direct result of inadequate virus-specific CD4 + T cells in persistent HCV infection. In the minority of patients who achieve spontaneous clearance of HCV infection, functional effector T cells are present, and T-reg cells are not strongly activated. 11 A previous study indicated that patients with acute HCV infection who develop chronicity versus spontaneous resolution exhibit temporal changes in T-reg cell function; the resolution of disease was associated with a relative loss of functional suppression. 12 It is possible that repetitive viral antigenic stimulation alters the function of T-reg cells over time. However, the primary genetic determinant of the virological outcome in HCV infection is not linked to T-cell immunity but to innate immunity. Polymorphisms in the gene encoding IL-28B powerfully predict the probability of self-cure in HCV infection. Chronic HCV-infected patients with the TT-IL28B rs12979860 genotype (unfavorable genotype) exhibit significantly increased frequencies of the T-reg cell population compared with the CT and CC genotypes. 13 One possible explanation is that in chronically HCV-infected individuals, the primary defect is the lack of a favorable IL-28B genotype, resulting in sustained viremia, the presence of HCVc, and the activation of T-reg cells. In the majority of chronic HCV-infected patients, high numbers of CD4 + CD25 + FoxP3 + T-reg cells accumulated in the HCV-infected liver display a highly activated and differentiated effector/memory phenotype and may be involved in limiting HCV-induced fibrogenesis. 14 Liver pathology is relatively mild and progresses slowly, which may be a benefit of these T-reg cells. As a consequence, the trade-off is that effective immune control is not achieved, resulting in the maintenance of chronic HCV infection. We conclude that the effect of HCVc on T-reg cells indicates that the activated T-reg cells and non-functional effector cells are consequences rather than causes of chronic infection. The dysfunctional effector CD4 + T cells and T-reg cells could, therefore, constitute a biomarker of viremia.
During the past 5 years, direct-acting antiviral agents (DAA) have revolutionized HCV therapy, and their high efficacy results in 90% virus clearance. However, HCV infection remains a significant cause of morbidity and mortality. Although these drugs offer hope to identified infected individuals in resource-rich settings, they are not affordable to many patients. Furthermore, many cases of HCV infection are sub-clinical, and these patients do not seek medical attention until liver disease has developed. In addition, a few problems are associated with interferon-free DAAs therapy, such as the concern that HCV will evolve resistance over time. DAAs do not protect against reinfection or reverse all complications of liver disease. One report describes an unexpectedly high rate of tumor recurrence coinciding with HCV clearance after interferon-free therapy. 15 Thus, in the long term, effective therapy may depend on manipulation of the host immune system to achieve suppression of the virus in the large number of chronically infected individuals. It is likely that nextgeneration therapies will need to address immune dysfunction. The question is which dysfunction to target. In the case of the specific effect of HCVc in activating T-reg cells that suppress effector CD4 + T cells, we might interpret the data as demonstrating that T-reg cells are the cause of failed CD4 + and CD8 + T-cell immunity. Then, we might seek to eliminate or inactivate T-reg cells to tip the balance in the patient's favor. Although T-reg cell depletion of chronically infected TTR-NP mice led to functional restoration of LCMV-specific CD4 + and CD8 + T cell responses and viral clearance, 16 the depletion of CD4 + T cells before reinfection of two immune chimpanzees resulted in persistent HCV infection. 10 However, we consider that T-reg cells are no more than biomarkers of HCV viremia; thus, depleting these cells is likely to be a futile effort. T-reg cell depletion may result in better antiviral outcomes in HCV infection but potentially at the cost of increased immunopathology, such as liver pathology 14 and hepatitis C-mixed cryoglobulinemia vasculitis. 17 Figure 1 T-reg cells are triggered and expanded in diverse ways in HCV infection. HCV not only induces T-regs expension directly, but also acts via other cells indirectly, including infected hepatocytes, suppressive monocytes (MDSCs), and NK-reg.
